Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes

Diabetes Care

Volumn 34, Issue 4, 2011, Pages 1000-1005

  Conway, Baqiyyah N ^a   Aroda, Vanita R ^b   Maynard, John D ^c   Matter, Nathaniel ^c   Fernandez, Stephen ^b   Ratner, Robert E ^b   Orchard, Trevor J ^d  

^a VANDERBILT UNIVERSITY   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c VeraLight ^*  (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; AUTONOMIC NEUROPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEUROPATHY; DISEASE DURATION; DISEASE MARKER; DISTAL SYMMETRICAL POLYNEUROPATHY; ELECTROCARDIOGRAM; FEMALE; FLUORESCENCE; HEART RATE; HUMAN; HYPERPNEA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SKIN INTRINSIC FLUORESCENCE;

ADULT; AREA UNDER CURVE; AUTONOMIC NERVOUS SYSTEM; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; ELECTROCARDIOGRAPHY; FEMALE; FLUORESCENCE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYNEUROPATHIES; SKIN;

EID: 79956208751     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1791     Document Type: Article

References (24)

1. Kaufman F (Ed.). Medical Management of Type 1 Diabetes. Alexandria, VA, American Diabetes Association, 2008
2. Ayad F, Belhadj M, Pariés J, Attali JR, Valensi P. Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. Diabet Med 2010;27:804-811
3. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: ameta-analysis. Diabetes Care 2003;26:1895-1901
4. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabet Med 1998;15:97-112 (Pubitemid 28096274)
5. Hull E, Ediger M, Unione A, Deemer E, Stroman M, Baynes J. Noninvasive, optical detection of diabetes: model studies with porcine skin. Opt Express 2004;12:4496-4510
6. Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997;40:1380-1387 (Pubitemid 28004930)
7. Ryle C, Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics. J Neurol Sci 1995;129:62-68
8. Vlassara H, Brownlee M, Cerami A. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J Exp Med 1984;60:197-207 (Pubitemid 14089790)
9. Cellek S, Qu W, Schmidt AM, Moncada S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia 2004;47:331-339 (Pubitemid 38315371)
10. Monnier V, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Diabetes 1999;48:870-880
11. Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM: Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990;13:741-747 (Pubitemid 20207423)
12. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116-1124
13. DOH. National Institute of Health, Education, and Welfare, Lipid Research Clinics Program. Washington, DC, U.S. Govt. Printing Office, 1975
14. The Hypertension Detection and Follow-Up Program: Hypertension Detection and Follow-Up Program Cooperative Group. Prev Med 1976;5:207-215
15. Group DR. Manual of Operations for the Diabetes Control and Complications Trial. Washington, DC, U.S. Department of Commerce, 1987
16. Maser RE, Nielsen VK, Bass EB, et al. Measuring diabetic neuropathy: assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 1989;12:270-275 (Pubitemid 19092237)
17. Stella P, Ellis D, Maser RE, Orchard TJ. Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes: incidence and predictors. J Diabetes Complications 2000;14:1-6 (Pubitemid 30484031)
18. Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 2007;30:1120-1124 (Pubitemid 46684635)
19. Ediger MN, Olson BP, Maynard JD. Non-invasive optical screening for diabetes. J Diabetes Sci Tech 2009;3:776-780
20. Semmes J, Weinstein S, Ghent L, Teuber H. Somatosensory Changes After Penetrating BrainWounds in Man. Cambridge, MA, Harvard University Press, 1960
21. Misur I, Zarković K, Barada A, Batelja L, Milicević Z, Turk Z. Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy. Acta Diabetol 2004;41:158-166 (Pubitemid 40174991)
22. Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005;48:1637-1644 (Pubitemid 41175518)
23. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005;1043:461-466 (Pubitemid 41123934)
24. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002;99:15596-15601 (Pubitemid 35403978)